Safety and immunogenicity of inactivated SARS-CoV-2 vaccine in high-risk occupational population: a randomized, parallel, controlled clinical trial

被引：0
|
作者：
Yongliang Feng
Jing Chen
Tian Yao
Yue Chang
Xiaoqing Li
Rongqin Xing
Hong Li
Ruixue Xie
Xiaohong Zhang
Zhiyun Wei
Shengcai Mu
Ling Liu
Lizhong Feng
Suping Wang
机构：
[1] Shanxi Medical University,Department of Epidemiology, School of Public Health
[2] Shanxi Medical University,Center of Clinical Epidemiology and Evidence Based Medicine
[3] Shanxi Provincial Center for Disease Control and Prevention,undefined
[4] Shanxi Provincial Key Laboratory for Major Infectious Disease Response,undefined
[5] Outpatient Department of Shanxi Aviation Industry Group Co. LTD,undefined
来源：
Infectious Diseases of Poverty | / 10卷
关键词：
COVID-19; Inactivated SARS-CoV-2 vaccine; Immunogenicity; Safety; High-risk occupational population; Randomized controlled trial;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Safety and immunogenicity of inactivated SARS-CoV-2 vaccine in high-risk occupational population: a randomized, parallel, controlled clinical trial
    Feng Yongliang
    Chen Jing
    Yao Tian
    Chang Yue
    Li Xiaoqing
    Xing Rongqin
    Li Hong
    Xie Ruixue
    Zhang Xiaohong
    Wei Zhiyun
    Mu Shengcai
    Liu Ling
    Feng Lizhong
    Wang Suping
    贫困所致传染病（英文）, 2021, 10 (06) : 27 - 37
  • [2] Safety and immunogenicity of inactivated SARS-CoV-2 vaccine in high-risk occupational population: a randomized, parallel, controlled clinical trial
    Feng, Yongliang
    Chen, Jing
    Yao, Tian
    Chang, Yue
    Li, Xiaoqing
    Xing, Rongqin
    Li, Hong
    Xie, Ruixue
    Zhang, Xiaohong
    Wei, Zhiyun
    Mu, Shengcai
    Liu, Ling
    Feng, Lizhong
    Wang, Suping
    INFECTIOUS DISEASES OF POVERTY, 2021, 10 (01)
  • [3] CoronaVac: A review of efficacy, safety, and immunogenicity of the inactivated vaccine against SARS-CoV-2
    Jin, Lairun
    Li, Zhuopei
    Zhang, Xiaoyin
    Li, Jingxin
    Zhu, Fengcai
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2022, 18 (06)
  • [4] A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine
    Chu, Laurence
    McPhee, Roderick
    Huang, Wenmei
    Bennett, Hamilton
    Pajon, Rolando
    Nestorova, Biliana
    Leav, Brett
    VACCINE, 2021, 39 (20) : 2791 - 2799
  • [5] Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine: Preclinical Studies
    Kandeil, Ahmed
    Mostafa, Ahmed
    Hegazy, Rehab R.
    El-Shesheny, Rabeh
    El Taweel, Ahmed
    Gomaa, Mokhtar R.
    Shehata, Mahmoud
    Elbaset, Marawan A.
    Kayed, Ahmed E.
    Mahmoud, Sara H.
    Moatasim, Yassmin
    Kutkat, Omnia
    Yassen, Noha N.
    Shabana, Marwa E.
    GabAllah, Mohamed
    Kamel, Mina Nabil
    Abo Shama, Noura M.
    El Sayes, Mohamed
    Ahmed, Amira N.
    Elalfy, Zahraa S.
    Mohamed, Bassim M. S. A.
    Abd El-Fattah, Safa N.
    El Hariri, Hazem Mohamed
    Abdel Kader, Mona
    Azmy, Osama
    Kayali, Ghazi
    Ali, Mohamed A.
    VACCINES, 2021, 9 (03) : 1 - 15
  • [6] Immunogenicity and Safety of a 3-Dose Regimen of a SARS-CoV-2 Inactivated Vaccine in Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
    Liu, Jiankai
    Huang, Baoying
    Li, Guifan
    Chang, Xianyun
    Liu, Yafei
    Chu, Kai
    Hu, Jialei
    Deng, Yao
    Zhu, Dandan
    Wu, Jingliang
    Zhang, Li
    Wang, Meng
    Huang, Weijin
    Pan, Hongxing
    Tan, Wenjie
    JOURNAL OF INFECTIOUS DISEASES, 2022, 225 (10) : 1701 - 1709
  • [7] The immunogenicity of Alum plus CpG adjuvant SARS-CoV-2 inactivated vaccine in mice
    Yang, Jie
    Li, Boran
    Yang, Dongsheng
    Wu, Jie
    Yang, Anna
    Wang, Wenhui
    Lin, Fengjie
    Wan, Xin
    Li, YuWei
    Chen, Zhuo
    Lv, Shiyun
    Pang, Deqin
    Liao, Wenbo
    Meng, Shengli
    Lu, Jia
    Guo, Jing
    Wang, Zejun
    Shen, Shuo
    VACCINE, 2023, 41 (41) : 6064 - 6071
  • [8] Safety and Immunogenicity Outcomes of an Inactivated Viral Vaccine against SARS-CoV-2 (Covaxin®)
    Sinha, Parul
    Gupta, Megha
    Vijayvergia, Varunika
    Jain, Sushil Kumar
    Jain, Dinesh Kumar
    Gupta, Sandeep
    Rathore, Monika
    Vyas, Nitya
    JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2022, 16 (09) : DC12 - DC17
  • [9] Phase II randomized, double blind, placebo controlled, clinical trial of safety and immunogenicity of an inactivated SARS-CoV-2 vaccine FAKHRAVAC in adults aged 18–70 years
    Fatemeh Gholami
    Ramin Hamidi Farahani
    Ahmad Karimi Rahjerdi
    Mohammadreza Ahi
    Ali Sheidaei
    Kimiya Gohari
    Zahra Rahimi
    Akram Ansarifar
    Pouria Basiri
    Milad Moradi
    Arash Jahangiri
    Kosar Naderi
    Soheil Ghasemi
    Pezhman Khatami
    Mohsen Honari
    Samane Khodaverdloo
    Mohammad Shooshtari
    Hajar Mehr Azin
    Sohrab Moradi
    Batool Shafaghi
    Hossein Allahyari
    Arina Monazah
    Ali Khodaei Poor
    Zahra Taghva
    Hooman Bakhshande
    Mohammad Karimi Nia
    Masoud Solaymani Dodaran
    Mohsen Forooghizade
    BMC Infectious Diseases, 23
  • [10] Immunogenicity and safety of boosting with a recombinant two-component SARS-CoV-2 vaccine: two randomized, parallel-controlled, phase 2 studies
    Balgos, Abundio
    Hannawi, Suad
    Chen, Wen-Li
    Abuquta, Alaa
    Safeldin, Linda
    Hassan, Aala
    Alamadi, Ahmad
    Tirador, Louie
    Jaen, Anjuli May
    Villalobos, Ralph Elvi
    Mo, Chen
    Yue, Zi-Jing
    Ma, Ying
    Wang, Qing-Shuang
    Wen, Ren-Du
    Yao, Zheng
    Yu, Jia-Ping
    Yao, Wen-Rong
    Zhang, Jian-Hui
    Hong, Kun-Xue
    Liu, Yong
    Li, Jing-Xin
    EXPERT REVIEW OF VACCINES, 2024, 23 (01) : 419 - 431
12345